TGFB1 and neoplasm: Both qRT‐PCR and immunoblotting analyses revealed a significant downregulation of the TGF‐β1 expression in the tumor of mice treated with these divalent and trivalent therapies, compared to monotherapies, which was 6‐ and 2.5‐fold (p < 0.01) lower for the TGF‐β1 mRNA levels (Figure 3F), 3‐ and 3‐fold (p < 0.05) lower for the TGF‐β1 protein levels (Figure 3G), respectively.